Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5] Offering Details - Trevi announced a public offering of 17,400,000 shares of common stock at a price of $5.75 per share, aiming for total proceeds of$100 million before deductions [1] - The offering includes a 30-day option for underwriters to purchase up to 2,610,000 additional shares at the public offering price [1] - The offering is expected to close on or about June 5, 2025, subject to customary closing conditions [1] Underwriters - Morgan Stanley, Leerink Partners, Stifel, and Cantor are acting as joint book-running managers for the offering [2] Regulatory Information - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3]